# A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers

> **NCT05737082** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 44 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HCP2201
- **DRUG:** RLD2205
- **DRUG:** RLD2206

## Key facts

- **NCT ID:** NCT05737082
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-30
- **Primary completion:** 2023-05-14
- **Final completion:** 2023-05-14
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737082, "A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05737082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*